SQ-LIP-000012 · v1.6 (archived) · View current version →

Do hormones and heredity influence the onset of lipedema?

Knowledge freshness = share of the 31 indexed evidence sources from the last 5 years (newest 2026, oldest 2010) . Low freshness flags an ageing evidence base — not that the answer is wrong.

Evidence over time

supporting   contradicting   refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.

Supporting claims

• SCR-LIP-000004 supporting
  Lipedema is a multifactorial disorder whose symptoms are closely linked to female hormonal transitions (puberty, pregnancy, menopause) and to chronic low-grade inflammation, on a polygenic predisposition.
  Brazilian Consensus Statement on Lipedema using the Delphi methodology — Amato et al. (2025) · Amato ACM, 2020
• SCR-LIP-000046 supporting
  Several findings suggest a hereditary predisposition to lipedema, with frequent family history among affected women.
  Brazilian Consensus Statement on Lipedema using the Delphi methodology — Amato et al. (2025)
• SCR-LIP-000039 supporting
  In women with lipedema, hormonal contraceptive use is associated with self-reported symptom worsening (58.8% of users; 15.1% reporting symptom onset coinciding with contraceptive initiation).
  Association Between Hormonal Contraceptive Use and Lipedema: A Cross-Sectional Study With 637 Brazilian Women — Amato et al. (2025)
• SCR-LIP-000109 supporting
  A systematic review identified four distinct pathophysiological hypotheses linking hormonal dysregulation—particularly estrogen metabolism and receptor function, growth hormone imbalance, and adipokine/leptin-related adipose stem cell alterations—to lipedema development, with possible genetic susceptibility components.
  Lower limb lipoedema - male patient — Vargas (2026) · Impact of hormones on lipedema development: a systematic literature review — Lüchinger et al. (2026)
• SCR-LIP-000110 supporting
  Lipedema is described as an estrogen-regulated polygenic disorder that manifests almost exclusively in women, with onset at hormonal transition phases (puberty, pregnancy, menopause), family aggregation in at least 16% of cases, and a pathological ERα/ERβ receptor pattern in white adipose tissue driving site-specific lipogenesis.
  Lipödem – Grundlagen und aktuelle Thesen zum Pathomechanismus — Wiedner et al. (2018)
• SCR-LIP-000153 supporting
  In a survey of 209 lipedema patients, symptom onset clustered in adolescence (mean age 16±9 years, 32.5% at ages 14-18), family history was common (affected grandmothers 35.4%, mothers 29.7%, aunts 23.0%), and 30.5% of premenopausal patients had sex-hormone imbalances, consistent with hormonal and hereditary contributions to lipedema onset.
  New Insights on Lipedema: The Enigmatic Disease of the Peripheral Fat — Bauer et al. (2019)
• SCR-LIP-000154 supporting
  This critical review proposes an integrative pathomechanism in which lipedema is an estrogen-regulated polygenetic disease, citing up to 60% of cases suggesting autosomal dominant inheritance with incomplete penetrance (Child et al., 330 relatives) and manifestation paralleling feminine hormonal changes, alongside estrogen receptor differences (decreased ERα, increased ERβ in the gluteal region) and animal models (PROX1+/-, VEGFR-3 mutants).
  Pathophysiological dilemmas of lipedema — Szél et al. (2014)
• SCR-LIP-000155 supporting
  In a cross-sectional study of Saudi lipedema patients, 49% reported puberty and 22% reported pregnancy as perceived triggering events, and 46% had a positive family history (predominantly mothers and sisters).
  Characteristics and Clinical Features of Patients with Lipedema in Saudi Arabia: A Cross-sectional Comprehensive Assessment — Alosaimi et al. (2024)
• SCR-LIP-000156 supporting
  A case report of idiopathic lipedema in a 62-year-old male—only the third such male case reported worldwide—notes that two of the three known male cases had associated hormonal alterations (alcoholic cirrhosis; type 1 diabetes plus alcohol abuse), and the near-exclusive female predominance is cited as suggesting a hormonal role in pathogenesis.
  DOI:10.3205/iprs000161
• SCR-LIP-000157 supporting
  This systematic review reports familial incidence of lipedema in 15% of first-degree female relatives consistent with X-linked dominant or autosomal dominant inheritance with incomplete penetrance, identifies an AKR1C1 missense variant (a gene involved in progesterone metabolism) as the first mutated gene in a family with primary non-syndromic lipedema, and notes hormonal/progesterone-pathway involvement.
  Lipedema Research—Quo Vadis? — Ernst et al. (2023)
• SCR-LIP-000219 supporting
  In a series of 67 probands, 14.9% had at least one affected first-degree relative (all affected relatives female), X-chromosome linkage analysis in the largest family excluded X-linked dominant inheritance (lod scores < -2) favoring autosomal dominant inheritance with sex limitation, and onset at puberty in 55% of probands plus near-exclusive female occurrence suggested estrogen-dependent expression.
  Lipedema: An inherited condition — Child et al. (2010)
• SCR-LIP-000220 supporting
  This narrative review reports genetic evidence (305 candidate genes via next-generation sequencing in 162 patients; 18 GWAS risk loci including VEGFA and GRB14-COBLL1 validated in UK Biobank; monogenic AKR1C1 and PIT1 mutations affecting progesterone and growth-hormone/prolactin pathways) supporting both hereditary and hormonal influences on lipedema onset.
  Lipedema: Progress, Challenges, and the Road Ahead — Cifarelli (2025)
• SCR-LIP-000221 supporting
  This integrative review proposes that menopause acts as a critical inflection point in lipedema progression via estrogen receptor imbalance (downregulated ERα and upregulated ERβ in affected tissue), increased local intracrine estradiol production through elevated aromatase (CYP19A1) and 17β-HSD1 with deficient 17β-HSD2, and progesterone resistance, reframing lipedema as an estrogen-dependent disorder.
  Menopause as a Critical Turning Point in Lipedema: The Estrogen Receptor Imbalance, Intracrine Estrogen, and Adipose Tissue Dysfunction Model — Pinto da Costa Viana et al. (2025)
• SCR-LIP-000222 supporting
  This comparative narrative review reports that lipedema is almost exclusively found in women and typically begins during periods of hormonal change (puberty, pregnancy, menopause), and notes heritability/genetic markers as part of its genetics domain.
  Current Mechanistic Understandings of Lymphedema and Lipedema: Tales of Fluid, Fat, and Fibrosis — Duhon et al. (2022)
• SCR-LIP-000223 supporting
  This multidisciplinary review reports that lipedema shows familial history in 30-89% of cases with polygenic GWAS findings (loci in CPE, ZNF25, ZNF33A linked to estrogen biology, plus VEGFA and GRB14-COBLL1, and an AKR1C1 missense variant) and that onset or worsening clusters at hormonal transitions—puberty (15.7-67.3%), pregnancy/lactation (9.5-63.1%), and menopause (1.9-21%)—with estradiol altering ERα/ERβ and PPAR-γ2 expression in lipedema-derived adipose stem cells.
  Unraveling lipedema: comprehensive insights and the path to future discoveries — Faria et al. (2025)
• SCR-LIP-000224 supporting
  In a rigorously defined UK lipedema cohort (n=130), onset was frequently associated with hormonal changes (puberty, pregnancy, menopause), and the first dedicated GWAS identified a suggestive genetic locus (rs1409440, OR_meta 2.01, P_meta 4×10⁻⁶) upstream of LHFPL6, replicated in an independent 100,000 Genomes cohort.
  Investigation of clinical characteristics and genome associations in the ‘UK Lipoedema’ cohort — Grigoriadis et al. (2022) · DOI:10.1101/2021.06.15.21258988
• SCR-LIP-000225 supporting
  This review proposes that dysregulated estrogen signaling in adipose tissue—via an increased ERα/ERβ ratio in gluteofemoral adipocytes or excessive local paracrine estrogen production by adipocyte steroidogenic enzymes—drives the excessive subcutaneous fat accumulation in lipedema, and cites whole-exome sequencing linking lipedema to variants in sex hormone genes, with onset coinciding with hormonal fluctuation periods such as puberty, pregnancy, and menopause.
  Lipedema and the Potential Role of Estrogen in Excessive Adipose Tissue Accumulation — Katzer et al. (2021)
• SCR-LIP-000226 supporting
  A GWAS of an inferred lipedema phenotype in UK Biobank women identified 18 genome-wide significant loci (SNP heritability ~5.13%), including RSPO3 (OR=1.24), GRB14-COBLL1, VEGFA, and ADAMTS9 (some replicated in an independent clinically-diagnosed lipedema cohort), with genetic correlations to body fat, leptin levels, and age at menopause.
  Genome-wide association study of a lipedema phenotype among women in the UK Biobank identifies multiple genetic risk factors — Klimentidis et al. (2023)
• SCR-LIP-000227 supporting
  Family-based DNA sequencing of 31 individuals from 9 lipedema families identified candidate variants in 469 genes with no single Mendelian causative gene, supporting polygenic genetic heterogeneity (consistent with positive family history in 60-80% of cases), with enrichment in vasopressin receptor activity (AVPR1A, AVPR2), microfibril binding, and patched binding gene ontology categories.
  A Family-Based Study of Inherited Genetic Risk in Lipedema — Morgan et al. (2024)
• SCR-LIP-000228 supporting
  A systematic review of genetic data proposes that primary lipedema follows an autosomal dominant inheritance pattern with incomplete penetrance and sex-limited expression (predominantly affecting women), with positive family history self-reported in up to 64% of women, and identifies syndromic forms linked to hormonal regulators including POU1F1A (Pit-1 regulating GH, PRL, TSH) and NSD1 (potentiating androgen receptor transactivation and estrogen-mediated tissue expansion).
  DOI:10.26355/eurrev_201907_18292
• SCR-LIP-000229 supporting
  This narrative review reports that lipedema onset is associated with periods of hormonal fluctuation (puberty, pregnancy, menopause) and describes estrogen-dependent mechanisms (increased aromatase CYP19A1, estrogen-induced ZNF423 hyperproliferation), alongside a proposed female-preferential autosomal dominant inheritance pattern.
  Lipedema: Insights into Morphology, Pathophysiology, and Challenges — Poojari et al. (2022)
• SCR-LIP-000230 supporting
  This review reports that lipedema develops or worsens during hormonal-change windows (puberty, pregnancy, menopause, oral contraceptives), with ~20% of cases identified at menopause and ~67% of patients reporting symptom exacerbation at its onset, and proposes an estrogen-receptor imbalance (decreased ERalpha/increased ERbeta) in affected adipose tissue as a central mechanism.
  Lipedema: From Women’s Hormonal Changes to Nutritional Intervention — Tomada (2025)
• SCR-LIP-000231 supporting
  This review proposes AKR1C enzymes (AKR1C1-4) as a central biological pathway linking rare familial mutations (e.g., AKR1C1 L213Q segregating with lipedema across 3 generations, AKR1C2 Ser320PheTer2) and common regulatory polymorphisms (rs28571848, rs34477787) to lipedema through altered steroid hormone metabolism in gluteofemoral subcutaneous adipose tissue, with environmental endocrine disruptors and hormones converging on the same hereditary pathway.
  From rare familial mutations to multifactorial disease: aldo-keto reductase 1C enzymes as a central biological pathway in lipedema — Vainberg et al. (2026)
• SCR-LIP-000232 supporting
  This review synthesizes evidence that estrogen and its receptors (ERα, ERβ, GPER) influence lipedema pathogenesis, noting disease onset/aggravation during hormonal-fluctuation windows (puberty, pregnancy, menopause) and that altered ER expression in gluteofemoral subcutaneous adipose tissue (reduced ERα, increased ERβ) parallels the regional fat accumulation characteristic of lipedema, affecting ~11% of women.
  Estrogen as a Contributing Factor to the Development of Lipedema — Al-Ghadban et al. (2021)
• SCR-LIP-000313 supporting
  A scoping review of 25 studies reports that lipedema symptom onset clusters at reproductive hormonal milestones (puberty/adolescence in 62.2-72.0% of cohorts, worsening in pregnancy in 53.0% and menopausal transition in 67.9%), with elevated hormone-sensitive comorbidities (PCOS 12.6-17.1%, autoimmune thyroiditis up to 35.5%) and molecular findings including loss-of-function variants in AKR1C1/AKR1C2, aromatase (CYP19A1) upregulation in adipose tissue, and altered estrogen receptor balance.
  DOI:10.20944/preprints202512.2108.v1
• SCR-LIP-000314 supporting
  This narrative review proposes that lipedema involves a common genetic alteration—an imbalance of estradiol receptors (ERα > ERβ) in adipose tissue present in all cases—combined with physiological hormonal fluctuations (puberty, pregnancy, menopause), endocrine disruptors, and estrogen-dependent gynecological disorders, citing associations such as menstrual irregularities (43%) and PCOS (17%) in women with lipedema.
  DOI:10.9734/jammr/2025/v37i25731
• SCR-LIP-000315 supporting
  Whole-exome sequencing in a family with autosomal dominant nonsyndromic primary lipedema identified the AKR1C1 c.638T>A (p.L213Q) variant segregating perfectly with the disease in 3 affected members (puberty onset in all) and absent in 9 unaffected members, with molecular dynamics and QSAR predicting partial loss of 20α-HSD function that may promote lipogenesis via reduced progesterone catabolism.
  DOI:10.3390/ijms21176264

Contradictory claims

• None indexed yet.

Refining / context

• SCR-LIP-000111 context
  A systematic review of lipedema pathology found that testosterone and estradiol showed no significant difference versus controls in plasma analysis, while the condition almost exclusively affects females and its fundamental etiology remains largely uncertain despite growing molecular and histological research.
  Auf der Suche nach der Evidenz: Eine systematische Übersichtsarbeit zur Pathologie des Lipödems — Funke et al. (2023)

Major uncertainty

Causation and mechanism remain unproven: the evidence base is dominated by narrative reviews, consensus, and cross-sectional/self-report surveys with high risk of recall/selection bias, and the genetic signals are largely suggestive (not genome-wide significant), polygenic and heterogeneous, with monogenic AKR1C1 findings confined to rare single families. Critically, the highest-quality study (PRISMA systematic review) found no difference in systemic testosterone or estradiol, so the proposed tissue-level estrogen-receptor/steroid-metabolism mechanisms remain hypothesized rather than confirmed, and no prospective or interventional data establish that hormones or inherited variants cause onset rather than merely correlate with it.

Version history

• SQ-LIP-000012 · v1.6 — 2026-05-31 — This update added four supporting low/very-low-quality sources—a scoping review of 25 studies and a narrative review quantifying hormonal-milestone onset and hormone-sensitive comorbidities, a 130-patient UK GWAS linking loci to hormone biosynthesis/lipid hydroxylation, and a whole-exome study showing the AKR1C1 p.L213Q variant segregating perfectly across an autosomal-dominant family—reinforcing the existing hormonal and hereditary evidence without altering the overall direction or the high-quality finding of no systemic sex-hormone difference. · view this version
• SQ-LIP-000012 · v1.5 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
• SQ-LIP-000012 · v1.4 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
• SQ-LIP-000012 · v1.3 — 2026-05-31 — This update added a substantial body of genetic evidence (multiple GWAS including UK Biobank loci such as RSPO3/VEGFA/ADAMTS9 and a dedicated cohort locus near LHFPL6, family-based sequencing supporting polygenic heterogeneity, linkage analysis excluding X-linked dominant inheritance, and additional AKR1C/POU1F1A hormone-pathway findings) plus several mechanistic reviews reinforcing tissue-level estrogen-receptor imbalance and menopause as an inflection point, strengthening but not changing the prior affirmative, evidence-bounded answer. · view this version
• SQ-LIP-000012 · v1.2 — 2026-05-31 — This update added six supporting items—survey and cross-sectional data on adolescent onset timing and high familial prevalence, two reviews proposing estrogen-regulated polygenic mechanisms with specific candidate genes (AKR1C1 progesterone-metabolism variant, familial Pit1 mutation) and inheritance patterns up to 60%, and a rare male case report invoking a hormonal hypothesis—strengthening the breadth of evidence for hormonal and hereditary influence without altering the prior cautious conclusion. · view this version
• SQ-LIP-000012 · v1.1 — 2026-05-31 — This update added a 2026 systematic review formalizing four hormonal pathophysiological hypotheses, a 2018 mechanistic review characterizing lipedema as an estrogen-regulated polygenic disorder with quantified family aggregation and ERα/ERβ receptor data, and a 2023 PRISMA-based systematic review providing the important counterpoint that circulating estradiol and testosterone levels are not significantly elevated versus controls—collectively deepening the mechanistic framing while introducing a key null finding on systemic hormone levels. · view this version
• SQ-LIP-000012 · v1.0 — 2026-05-30 — founding index (28 claims) · view this version

Key references

DOI:10.1590/1677-5449.202301832 · DOI:10.7759/cureus.99189 · DOI:10.53347/rid-217362 · DOI:10.1007/s00404-026-08318-1 · DOI:10.1055/a-0767-6842 · DOI:10.1055/a-2183-7414 · DOI:10.1097/prs.0000000000006280 · DOI:10.1016/j.mehy.2014.08.011 · DOI:10.1097/gox.0000000000006173 · DOI:10.3205/iprs000161 · DOI:10.3390/jpm13010098 · DOI:10.1002/ajmg.a.33313 · DOI:10.1111/obr.13953 · DOI:10.3390/ijms26157074 · DOI:10.3390/ijms23126621 · DOI:10.1038/s44324-025-00093-y · DOI:10.1371/journal.pone.0274867 · DOI:10.1101/2021.06.15.21258988 · DOI:10.3390/ijms222111720 · DOI:10.1038/s41431-022-01231-6 · DOI:10.1089/lrb.2023.0065 · DOI:10.26355/eurrev_201907_18292 · DOI:10.3390/biomedicines10123081 · DOI:10.3390/endocrines6020024 · DOI:10.4081/vl.2026.15495 · DOI:10.5772/intechopen.96402 · DOI:10.20944/preprints202512.2108.v1 · DOI:10.9734/jammr/2025/v37i25731 · DOI:10.3390/ijms21176264

← All questions